Cong‐Fei Xu
Impact in
- Biomaterials top 0.5%
- Nanoparticle-Based Drug Delivery
- Biomedical Engineering top 1%
- Nanoplatforms for cancer theranostics
- Graphene and Nanomaterials Applications
Papers in
- Immunology 22
- Immunotherapy and Immune Responses 14
- Immune Cell Function and Interaction 8
- Biomaterials 11
- Nanoparticle-Based Drug Delivery 11
- Co-authors
- Jun WangXianzhu YangSong ShenYang LiuZhiting CaoXiao‐Jiao DuHongjun LiYing‐Li Luo
- Journals
- Biomaterials (7 papers)Nature Communications (6 papers)Biomaterials Science (5 papers)Journal of Controlled Release (4 papers)Nano Today (4 papers)
- Partner nations
- ChinaUnited States
In The Last Decade
Cong‐Fei Xu
61 papers receiving 4.4k citations
Hit Papers
Peers
Comparison fields: 5 of 105
- Biomaterials 1.3k
- Biomedical Engineering 1.8k
- Immunology 827
- Molecular Biology 2.5k
- Business and International Management 48
Countries citing papers authored by Cong‐Fei Xu
This map shows the geographic impact of Cong‐Fei Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cong‐Fei Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cong‐Fei Xu more than expected).
Fields of papers citing papers by Cong‐Fei Xu
This network shows the impact of papers produced by Cong‐Fei Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cong‐Fei Xu. The network helps show where Cong‐Fei Xu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Cong‐Fei Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 2 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 1 | |
| 5 | 2025 | 6 | |
| 6 | 2025 | 5 | |
| 7 | 2025 | 1 | |
| 8 | 2025 | 0 | |
| 9 | 2024 | 7 | |
| 10 | 2023 | 7 | |
| 11 | 2023 | 13 | |
| 12 | 2023 | 16 | |
| 13 | 2022 | 33 | |
| 14 | 2022 | 1 | |
| 15 | 2019 | 151 | |
| 16 | 2019 | 77 | |
| 17 | 2018 | 89 | |
| 18 | 2016 | 100 | |
| 19 | 2016 | 99 | |
| 20 | 2016 | 64 |
About Cong‐Fei Xu
Cong‐Fei Xu is a scholar working on Immunology, Biomaterials, Oncology, Biomedical Engineering and Molecular Biology, having authored 65 papers that have together received 4.5k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (24 papers), Immunotherapy and Immune Responses (14 papers), Nanoplatforms for cancer theranostics (14 papers), CAR-T cell therapy research (14 papers), Nanoparticle-Based Drug Delivery (11 papers), Advanced biosensing and bioanalysis techniques (10 papers), Immune Cell Function and Interaction (8 papers) and Graphene and Nanomaterials Applications (6 papers). The work is most often cited by research in Biomaterials (1.3k citations), Biomedical Engineering (1.8k citations), Immunology (827 citations), Molecular Biology (2.5k citations) and Business and International Management (48 citations). Cong‐Fei Xu has collaborated with scholars based in China and United States. Frequent co-authors include Jun Wang, Xianzhu Yang, Song Shen, Yang Liu, Zhiting Cao, Xiao‐Jiao Du, Hongjun Li, Ying‐Li Luo, Jin‐Zhi Du and Chunyang Sun. Their work appears in journals such as Biomaterials, Nature Communications, Biomaterials Science, Journal of Controlled Release and Nano Today.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.